AU2004233966B2 - Pyrimidine derivatives useful for the treatment of diseases mediated by CRTH2 - Google Patents

Pyrimidine derivatives useful for the treatment of diseases mediated by CRTH2 Download PDF

Info

Publication number
AU2004233966B2
AU2004233966B2 AU2004233966A AU2004233966A AU2004233966B2 AU 2004233966 B2 AU2004233966 B2 AU 2004233966B2 AU 2004233966 A AU2004233966 A AU 2004233966A AU 2004233966 A AU2004233966 A AU 2004233966A AU 2004233966 B2 AU2004233966 B2 AU 2004233966B2
Authority
AU
Australia
Prior art keywords
amino
benzyl
acetic acid
dimethylamino
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004233966A
Other languages
English (en)
Other versions
AU2004233966A1 (en
Inventor
Kevin Bacon
Yuji Koriyama
Tai-Wei Ly
Yoshihisa Manabe
Hiroki Sato
Masanori Seki
Takuya Shintani
Hiromi Sugimoto
Kazuho Tanaka
Klaus Urbahns
Takashi Yoshino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GB007 Inc
Original Assignee
Actimis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actimis Pharmaceuticals Inc filed Critical Actimis Pharmaceuticals Inc
Publication of AU2004233966A1 publication Critical patent/AU2004233966A1/en
Application granted granted Critical
Publication of AU2004233966B2 publication Critical patent/AU2004233966B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2004233966A 2003-04-25 2004-04-14 Pyrimidine derivatives useful for the treatment of diseases mediated by CRTH2 Ceased AU2004233966B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03009384A EP1471057B1 (en) 2003-04-25 2003-04-25 Pyrimidinylacetic acid derivatives useful for the treatment of diseases mediated by CRTH2
EP03009384.3 2003-04-25
PCT/EP2004/003910 WO2004096777A1 (en) 2003-04-25 2004-04-14 Pyrimidine derivatives useful for the treatment of diseases mediated by crth2

Publications (2)

Publication Number Publication Date
AU2004233966A1 AU2004233966A1 (en) 2004-11-11
AU2004233966B2 true AU2004233966B2 (en) 2010-11-11

Family

ID=32946880

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004233966A Ceased AU2004233966B2 (en) 2003-04-25 2004-04-14 Pyrimidine derivatives useful for the treatment of diseases mediated by CRTH2

Country Status (32)

Country Link
US (2) US7812160B2 (enExample)
EP (2) EP1471057B1 (enExample)
JP (2) JP4671955B2 (enExample)
KR (1) KR101110491B1 (enExample)
CN (2) CN1809539B (enExample)
AR (1) AR043885A1 (enExample)
AT (2) ATE316077T1 (enExample)
AU (1) AU2004233966B2 (enExample)
BR (1) BRPI0409733A (enExample)
CA (1) CA2523439C (enExample)
CL (1) CL43596B (enExample)
CY (1) CY1111295T1 (enExample)
DE (2) DE60303238T2 (enExample)
DK (2) DK1471057T3 (enExample)
DO (1) DOP2004000875A (enExample)
ES (2) ES2257616T3 (enExample)
GT (1) GT200400079A (enExample)
HN (1) HN2004000129A (enExample)
IL (1) IL171566A (enExample)
MX (1) MXPA05011399A (enExample)
MY (1) MY147984A (enExample)
NO (1) NO20055588L (enExample)
NZ (1) NZ543693A (enExample)
PE (1) PE20050143A1 (enExample)
PL (1) PL1633726T3 (enExample)
PT (2) PT1471057E (enExample)
RU (1) RU2361865C2 (enExample)
SI (1) SI1633726T1 (enExample)
TW (1) TWI353980B (enExample)
UY (1) UY28286A1 (enExample)
WO (1) WO2004096777A1 (enExample)
ZA (1) ZA200508722B (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
DK1471057T3 (da) 2003-04-25 2006-05-15 Actimis Pharmaceuticals Inc Pyrimidinyleddikesyrederivater, der er egnede til behandlingen af sygdomme medieret af CRTH2
SA04250253B1 (ar) * 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
ES2775204T3 (es) * 2003-12-23 2020-07-24 Genentech Inc Nuevos anticuerpos anti IL13 y usos de los mismos
NZ548396A (en) 2004-01-31 2010-06-25 Actimis Pharmaceuticals Inc Imidazo[1,2-C]pyrimidinylacetic acid derivatives
WO2005095397A1 (en) 2004-03-11 2005-10-13 Actelion Pharmaceuticals Ltd Tetrahydropyridoindole derivatives
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
US8524715B2 (en) 2004-11-23 2013-09-03 Astrazeneca Ab Phenoxyacetic acid derivatives useful for treating respiratory diseases
RU2453540C2 (ru) 2005-04-21 2012-06-20 Лаборатуар Сероно С.А. 2,3-замещенные пиразинсульфонамиды в качестве ингибиторов crth2
PT1891075E (pt) 2005-05-24 2011-11-10 Merck Serono Sa Derivados espiro tricíclicos como moduladores do crth2
DOP2006000210A (es) 2005-10-04 2007-06-15 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds
EP1937632A1 (en) 2005-10-06 2008-07-02 Astra Zeneca AB Novel compounds
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
WO2007062677A1 (en) * 2005-11-30 2007-06-07 7Tm Pharma A/S Thiazolyl- and pyrimidinyl-acetic acids and their use as crth2 receptor ligands
BRPI0712301A2 (pt) * 2006-06-09 2012-01-17 Icos Corp composto, composição farmacêutica, método de antagonização de um receptor dp-2, e, uso de um composto
WO2008104869A1 (en) * 2007-02-26 2008-09-04 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
CN101772489B (zh) 2007-06-21 2013-02-20 艾克提麦斯医药品有限公司 一种crth2拮抗剂的胺盐
AU2008266853A1 (en) * 2007-06-21 2008-12-24 Actimis Pharmaceuticals, Inc. Particulates of a CRTH2 antagonist
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
PT2205569E (pt) * 2007-09-25 2012-05-25 Actimis Pharmaceuticals Inc Alquiltiopirimidinas como antagonistas de crth2
KR20100061746A (ko) 2007-09-25 2010-06-08 액티미스 파마수티컬스 인코포레이티드 Crth2 길항제로서의 2-s-벤질 치환된 피리미딘
WO2009099902A1 (en) 2008-02-01 2009-08-13 Amira Pharmaceuticals, Inc. N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
JP2011512359A (ja) 2008-02-14 2011-04-21 アミラ ファーマシューティカルズ,インク. プロスタグランジンd2受容体のアンタゴニストとしての環式ジアリールエーテル化合物
WO2009108720A2 (en) 2008-02-25 2009-09-03 Amira Pharmaceuticals, Inc. Antagonists of prostaglandin d2 receptors
JP2011518130A (ja) 2008-04-02 2011-06-23 アミラ ファーマシューティカルズ,インク. プロスタグランジンd2受容体のアミノアルキルフェニルアンタゴニスト
MX2010014172A (es) 2008-07-03 2011-02-22 Amira Pharmaceuticals Inc Antagonistas de receptores de prostaglandina d2.
WO2010027448A1 (en) * 2008-09-02 2010-03-11 Actimis Pharmaceuticals Inc. Isotopically enriched pyrimidin-5-yl acetic acid derivatives as crth2 antagonists
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010039977A2 (en) 2008-10-01 2010-04-08 Amira Pharmaceuticals, Inc. Heteroaryl antagonists of prostaglandin d2 receptors
WO2010042652A2 (en) 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
GB2465062B (en) 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
US8383654B2 (en) 2008-11-17 2013-02-26 Panmira Pharmaceuticals, Llc Heterocyclic antagonists of prostaglandin D2 receptors
CN102264704B (zh) * 2008-12-25 2014-06-04 大正制药株式会社 异喹啉衍生物
EP2393492A1 (en) * 2009-02-09 2011-12-14 Boehringer Ingelheim International GmbH New pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
US8273769B2 (en) 2009-02-12 2012-09-25 Merck Serono Sa Phenoxy acetic acid derivatives
WO2010094643A1 (en) * 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
KR20120038544A (ko) 2009-07-31 2012-04-23 판미라 파마슈티칼스, 엘엘씨 Dp2 수용체 길항제의 안과용 약학 조성물
SG10201404662YA (en) 2009-08-05 2014-10-30 Panmira Pharmaceuticals Llc Dp2 antagonist and uses thereof
GB0913636D0 (en) * 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
WO2011066176A1 (en) * 2009-11-24 2011-06-03 Boehringer Ingelheim International Gmbh Process for preparing a polymorph of the choline salt of a pyrimidin-5-yl acetic acid derivative
AU2011203649A1 (en) 2010-01-06 2012-06-14 Brickell Biotech, Inc. DP2 antagonist and uses thereof
DK2528901T3 (en) 2010-01-27 2015-08-17 Boehringer Ingelheim Int Pyrazole compounds as CRTH2 antagonists.
SG186737A1 (en) 2010-06-23 2013-02-28 Taisho Pharmaceutical Co Ltd Isoquinoline derivative
EP2590944B1 (en) 2010-07-05 2015-09-30 Actelion Pharmaceuticals Ltd. 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
EP2598145A1 (en) 2010-07-28 2013-06-05 Boehringer Ingelheim International GmbH Pharmaceutical composition for treatment of respiratory and inflammatory diseases
WO2012013566A1 (en) 2010-07-28 2012-02-02 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and inflammatory diseases
BR112013009519A2 (pt) 2010-10-20 2019-10-08 Eng Polymer Solutions Inc método para revestir um container de carga, e, método para fabricação de um container de carga resistente a corrosão
BR112013011737A2 (pt) 2010-11-15 2016-08-09 Univ Leuven Kath composto, uso de um composto composição farmacêutica, e, método de tratamento ou prevenção de uma infecção por hiv
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
TWI527809B (zh) 2011-01-24 2016-04-01 百靈佳殷格翰國際股份有限公司 作為crth2拮抗劑之吡唑化合物
EP2688882B1 (en) 2011-03-25 2015-05-13 Boehringer Ingelheim International GmbH Pyrazole compounds as crth2 antagonists
HRP20171287T1 (hr) * 2011-05-16 2017-11-17 Actimis Pharmaceuticals, Inc. Postupak za pripremu [4,6-bis-dimetilamino-2-[4-(4-trifluorometilbenzoil-amino)benzil]pirimidin-5-il]octene kiseline
JP2015500326A (ja) 2011-12-16 2015-01-05 アトピックス テラピューティクス リミテッド 好酸球性食道炎の治療のためのcrth2拮抗薬およびプロトンポンプ阻害薬の組み合わせ
EP2794563B1 (en) 2011-12-21 2017-02-22 Actelion Pharmaceuticals Ltd Heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
WO2014006585A1 (en) 2012-07-05 2014-01-09 Actelion Pharmaceuticals Ltd 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
US20140148470A1 (en) * 2012-11-23 2014-05-29 Boehringer Ingelheim International Gmbh Pyrimidine compounds for treating hairloss
TWI695831B (zh) 2014-09-13 2020-06-11 香港商南北兄弟藥業投資有限公司 Crth2拮抗劑化合物及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4239440A1 (enExample) * 1991-12-04 1993-06-09 Imperial Chemical Industries Plc, London, Gb
EP1170594A2 (en) * 2000-07-07 2002-01-09 Pfizer Products Inc. Methods for the identification of compounds useful for the treatment of disease states mediated by Prostaglandin D2

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790679A (fr) 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
JPH03112985A (ja) * 1989-09-28 1991-05-14 Morishita Pharmaceut Co Ltd N―(1h―テトラゾール―5―イル)―2―フェニル―5―ピリミジンカルボキシアミド類及びその合成用中間体
US6326368B1 (en) * 1996-03-27 2001-12-04 Dupont Pharmaceuticals Company Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof
CA2263198A1 (en) * 1996-09-06 1998-03-12 Nippon Kayaku Kabushiki Kaisha Novel acetamide derivatives and protease inhibitors
JP2001302667A (ja) 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
AU2001260081B2 (en) * 2000-05-22 2005-07-28 Leo Pharma A/S Benzophenones as inhibitors of il-1beta and tnf-alpha
SE0200411D0 (sv) * 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
EP1413306A1 (en) 2002-10-21 2004-04-28 Warner-Lambert Company LLC Tetrahydroquinoline derivatives as CRTH2 antagonists
EP1585511B1 (en) 2002-12-20 2013-01-23 Amgen Inc. Asthma and allergic inflammation modulators
DK1471057T3 (da) 2003-04-25 2006-05-15 Actimis Pharmaceuticals Inc Pyrimidinyleddikesyrederivater, der er egnede til behandlingen af sygdomme medieret af CRTH2
CN101772489B (zh) 2007-06-21 2013-02-20 艾克提麦斯医药品有限公司 一种crth2拮抗剂的胺盐
AU2008266853A1 (en) 2007-06-21 2008-12-24 Actimis Pharmaceuticals, Inc. Particulates of a CRTH2 antagonist

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4239440A1 (enExample) * 1991-12-04 1993-06-09 Imperial Chemical Industries Plc, London, Gb
EP1170594A2 (en) * 2000-07-07 2002-01-09 Pfizer Products Inc. Methods for the identification of compounds useful for the treatment of disease states mediated by Prostaglandin D2

Also Published As

Publication number Publication date
CL43596B (es) 2005-03-18
AU2004233966A1 (en) 2004-11-11
US20100322980A1 (en) 2010-12-23
JP2006524645A (ja) 2006-11-02
RU2005136655A (ru) 2006-06-10
EP1471057B1 (en) 2006-01-18
ES2257616T3 (es) 2006-08-01
JP5161290B2 (ja) 2013-03-13
US20070129355A1 (en) 2007-06-07
JP2011068657A (ja) 2011-04-07
KR20060089622A (ko) 2006-08-09
JP4671955B2 (ja) 2011-04-20
RU2361865C2 (ru) 2009-07-20
WO2004096777A1 (en) 2004-11-11
US7960393B2 (en) 2011-06-14
ATE316077T1 (de) 2006-02-15
DK1633726T3 (da) 2011-03-28
GT200400079A (es) 2004-11-30
KR101110491B1 (ko) 2012-01-31
SI1633726T1 (sl) 2011-04-29
MY147984A (en) 2013-02-28
HN2004000129A (es) 2009-05-14
NO20055588D0 (no) 2005-11-25
UY28286A1 (es) 2004-11-30
EP1471057A1 (en) 2004-10-27
NZ543693A (en) 2009-05-31
CN1809539A (zh) 2006-07-26
US7812160B2 (en) 2010-10-12
PL1633726T3 (pl) 2011-06-30
DOP2004000875A (es) 2004-10-31
AR043885A1 (es) 2005-08-17
DE60303238D1 (de) 2006-04-06
CA2523439C (en) 2012-06-19
CN101914065A (zh) 2010-12-15
MXPA05011399A (es) 2006-05-31
CA2523439A1 (en) 2004-11-11
EP1633726B1 (en) 2011-01-05
PT1471057E (pt) 2006-05-31
DE60303238T2 (de) 2006-09-14
HK1095320A1 (en) 2007-05-04
EP1633726A1 (en) 2006-03-15
CY1111295T1 (el) 2015-08-05
PE20050143A1 (es) 2005-04-01
NO20055588L (no) 2006-01-24
BRPI0409733A (pt) 2006-05-09
DK1471057T3 (da) 2006-05-15
IL171566A (en) 2011-03-31
CN1809539B (zh) 2012-05-09
DE602004030907D1 (de) 2011-02-17
ZA200508722B (en) 2006-12-27
ES2358424T3 (es) 2011-05-10
TW200505873A (en) 2005-02-16
TWI353980B (en) 2011-12-11
PT1633726E (pt) 2011-02-22
ATE494279T1 (de) 2011-01-15

Similar Documents

Publication Publication Date Title
AU2004233966B2 (en) Pyrimidine derivatives useful for the treatment of diseases mediated by CRTH2
JP4996257B2 (ja) イミダゾ[1,2−c]ピリミジニル酢酸誘導体
EP1654237A1 (en) 2-aminopyrimidine derivatives
HK1095320B (en) Pyrimidine derivatives useful for the treatment of diseases mediated by crth2

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired